EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Key Stakeholders' Knowledge, Opinions, and Interests on Real‐World Evidence in the Regulatory Process—Results of an EU ‐Wide Survey

Frank Lucas Depner iD, Martin Russek iD, Christoph Röthlein iD, Cornelia Becker iD, Jonas Peltner iD, Kerstin Pfeifer iD, Evy Reviers iD, Dirk De Valck iD, Julia Wicherski iD, Sirpa Hartikainen iD, Anna-Maija Tolppanen iD, Britta Haenisch iD

Clinical and Translational Science · 2025-12 · 18 (12)

DOI: 10.1111/cts.70454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 20.12.2025. Verfasst von Frank Lucas Depner und 11 weiteren Autor:innen. Beteiligte Einrichtung: German Center for Neurodegenerative Diseases (DZNE), Pharmacoepidemiology in Neurodegenerative Disorders, Bonn, Germany. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Stakeholder Participation, Health Knowledge, Attitudes, Practice. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Real‐world data (RWD) and real‐world evidence (RWE) are increasingly gaining attention in supporting drug regulatory decision making. This study assessed knowledge, opinions, and usage patterns of key stakeholders regarding the status of RWD/RWE and AI implementation in health technology assessment (HTA) and drug regulation and aimed to identify the primary obstacles hindering adoption of these technologies. Four surveys tailored to different stakeholders were created and disseminated online to the respective target groups, including I) regulatory authorities, HTA bodies, and the pharmaceutical industry, II) academia, III) payers, and IV) patients and physicians. The responses were analyzed using descriptive statistics or qualitative content analysis with inductive coding. The survey was active from May 6, 2024 to June 30, 2024. Altogether, 221 respondents participated in the survey. Among respondents from regulatory/HTA authorities or industry, 75.4% viewed RWD/RWE as important for future decision making. Respondents from this group already using RWD ( n = 56) most frequently reported obstacles regarding data quality (89.3%), data access (62.5%), and data‐coding standardization (57.1%). Patients and physicians predominantly had positive expectations about the use of RWD/RWE, and 94.3% indicated willingness to share healthcare data for research, but all respondents also expressed concerns, with data privacy being most frequently mentioned (75.5%). The results show that although stakeholders are optimistic about RWD/RWE implementation into regulatory practice, our survey suggests that successful implementation may benefit from further development in several areas, including guideline harmonization, RWD infrastructure optimization and accessibility, and professional education.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology Assessment, BiomedicalStakeholder ParticipationHealth Knowledge, Attitudes, PracticeHumansSurveys and QuestionnairesMaleFemaleDecision MakingAdultMiddle AgedEuropean Union

Stichwörter der Autor:innen

RWDRWEpatientsstakeholderssurvey

Autor:innen und Institutionen

  • German Center for Neurodegenerative Diseases (DZNE), Pharmacoepidemiology in Neurodegenerative Disorders, Bonn, Germany.
  • Federal Institute for Drugs and Medical Devices (BfArM), Research Division, Pharmacoepidemiology, Bonn, Germany.
  • European Organisation for Professionals and People with ALS (EUpALS), Leuven, Belgium.
  • School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
  • Center for Translational Medicine, University of Bonn, Bonn, Germany.

ORCID-Profile: Frank Lucas Depner, Martin Russek, Christoph Röthlein, Cornelia Becker, Jonas Peltner, Kerstin Pfeifer, Evy Reviers, Dirk De Valck, Julia Wicherski, Sirpa Hartikainen, Anna-Maija Tolppanen, Britta Haenisch

Zitieren

APA

Depner, F. L., Russek, M., Röthlein, C., Becker, C., Peltner, J., Pfeifer, K., Reviers, E., De Valck, D., Wicherski, J., Hartikainen, S., Tolppanen, A. M., & Haenisch, B. (2025). Key Stakeholders' Knowledge, Opinions, and Interests on Real‐World Evidence in the Regulatory Process—Results of an EU ‐Wide Survey. Clinical and Translational Science, 18(12). https://doi.org/10.1111/cts.70454

Vancouver

Depner FL, Russek M, Röthlein C, Becker C, Peltner J, Pfeifer K, et al. Key Stakeholders' Knowledge, Opinions, and Interests on Real‐World Evidence in the Regulatory Process—Results of an EU ‐Wide Survey. Clinical and Translational Science. 2025;18(12). doi:10.1111/cts.70454

BibTeX
@article{Depner2025,
  author = {Depner, Frank Lucas and Russek, Martin and Röthlein, Christoph and Becker, Cornelia and Peltner, Jonas and Pfeifer, Kerstin and Reviers, Evy and De Valck, Dirk and Wicherski, Julia and Hartikainen, Sirpa and Tolppanen, Anna-Maija and Haenisch, Britta},
  title = {Key Stakeholders' Knowledge, Opinions, and Interests on Real‐World Evidence in the Regulatory Process—Results of an EU ‐Wide Survey},
  journal = {Clinical and Translational Science},
  year = {2025},
  volume = {18},
  number = {12},
  doi = {10.1111/cts.70454}
}
Kostenlos starten →